Artwork by Holly Fischer [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0)], via Wikimedia Commons.
For our next journal club activity, we’ll be teaming up with the Nephrology Journal Club #NephJC to discuss the PRECISION Trial, published in NEJM: Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis by Nissen SE, et al. This article is open access via the NephJC blog post.
As many of you may recall, a portion of this data was presented during the #ACR16 late breaking abstract session: 1L: The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis.
- Session 1: Tuesday, January 24 at 9pm Eastern (find this in your time zone)
- Session 2: Wednesday January 25 at 3pm Eastern / 8pm GMT (find this in your time zone)
- For this session, we’ll plan on using the #NephJC hashtag for the discussion, since they’ll be hosting the session.
- As usual, we suggest using the website tchat.io in your desktop web browser as the best way to participate in the chat.